The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: a systematic review and meta-analysis
Abstract
OBJECTIVES: To study the comparative mortality associated with carbapenems and alternative antibiotics for the treatment of patients with extended-spectrum β-lactamase (ESBL)-positive Enterobacteriaceae bacteraemia. METHODS: We searched systematically PubMed and Scopus databases for studies providing data for mortality among patients treated with carbapenems, β-lactam/β-lactamase inhibitor combinations (BL/BLIs) or non-BL/BLIs (mainly cephalosporins and fluoroquinolones), preferably as monotherapy. Studies focusing on patients of all ages with community- and healthcare-associated bacteraemia were eligible. Data were pooled using the technique of meta-analysis. RESULTS: Twenty-one articles, studying 1584 patients, were included. Escherichia coli and Klebsiella pneumoniae were the most commonly studied bacteria. Delay in appropriate treatment up to 6 days was reported. Carbapenems were used mainly as definitive therapy. Carbapenems were associated with lower mortality than non- BL/BLIs for definitive [risk ratio (RR) 0.65, 95% CI 0.47-0.91] and empirical (RR 0.50, 95% CI 0.33-0.77) treatment. No statistically significant differences in mortality were found between carbapenems and BL/BLIs administered as definitive (RR 0.52, 95% 0.23-1.13) or empirical (RR 0.91, 95% CI 0.66-1.25) treatment. BL/BLIs were not associated with lower mortality than non-BL/BLIs administered either definitively (RR 1.59, 95% 0.83-3.06) or empirically (RR 0.82, 95% 0.48-1.41). Data regarding subgroups according to the setting, comorbidity and bacterial species could not be extracted. CONCLUSIONS: Based on data from non-randomized studies, carbapenems may be considered the treatment of choice for empirical treatment of patients with ESBL-producing Enterobacteriaceae bacteraemia. The role of BL/BLIs should be further evaluated for definitive treatment. Further research should focus on faster identification of ESBL-positive pathogens and potential differences in the treatment of each bacterial species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
Bioactive Microbial Metabolites: A Personal View
Bérdy, J. (2005) · The Journal of Antibiotics · doi:10.1038/ja.2005.1 · Cited by 3,170
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,044
Paterson, D. L., Ko, W.-C., Von Gottberg, A., Mohapatra, S., Casellas, J. M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K. P., Bonomo, R. A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/420816 · Cited by 571
Paterson, D. L., Ko, W.-C., Von Gottberg, A., Casellas, J. M., Mulazimoglu, L., Klugman, K. P., Bonomo, R. A., Rice, L. B., McCormack, J. G., & Yu, V. L. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.6.2206-2212.2001 · Cited by 546
Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E. M., Posteraro, B., Fiori, B., Citton, R., D'Inzeo, T., Fadda, G., Cauda, R., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01509-06 · Cited by 461
Paterson, D. L., Mulazimoglu, L., Casellas, J. M., Ko, W.-C., Goossens, H., Von Gottberg, A., Mohapatra, S., Trenholme, G. M., Klugman, K. P., McCormack, J. G., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313719 · Cited by 386
Community Infections Caused by Extended-Spectrum β-Lactamase–Producing Escherichia coli
Rodríguez-Baño, J., Alcalá, J. C., Cisneros, J. M., Grill, F., Oliver, A., Horcajada, J. P., Tórtola, T., Mirelis, B., Navarro, G., Cuenca, M., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.17.1897 · Cited by 379
Pitout, J. D. D. (2010) · Drugs · doi:10.2165/11533040-000000000-00000 · Cited by 376
Cited by
Harris, P. N. A., Tambyah, P. A., Lye, D. C., Mo, Y., Lee, T. H., Yilmaz, M., Alenazi, T. H., Arabi, Y., Falcone, M., Bassetti, M., et al. (2018) · JAMA · doi:10.1001/jama.2018.12163 · Cited by 774
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
Woerther, P.-L., Burdet, C., Chachaty, E., & Andremont, A. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-13 · Cited by 686
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P.-L., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 490
van der Zwaluw, K., de Haan, A., Pluister, G. N., Bootsma, H. J., de Neeling, A. J., & Schouls, L. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123690 · Cited by 486
Taplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6211 · Cited by 426
“• In the setting of a high prevalence of ESBL-producing gram-negative bacilli or fluoroquinolone resistance, hospital admission and initial empirical antibacterial treatment with a carbapenem should be considered.(21) Similarly, in a setting of high prevalence of other resistant organisms such as MRSA and VRE and conc…”
BackgroundSolomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications
Iredell, J., Brown, J., & Tagg, K. (2016) · BMJ · doi:10.1136/bmj.h6420 · Cited by 392
Infections Caused by Resistant Gram‐Negative Bacteria: Epidemiology and Management
Kaye, K. S., & Pogue, J. M. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1636 · Cited by 383
Hu, F.-P., Guo, Y., Zhu, D.-M., Wang, F., Jiang, X.-F., Xu, Y.-C., Zhang, X.-J., Zhang, C.-X., Ji, P., Xie, Y., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.01.001 · Cited by 361
Falagas, M. E., Lourida, P., Poulikakos, P., Rafailidis, P. I., & Tansarli, G. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01222-13 · Cited by 351
Self-citationExtended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities
Husna, A., Rahman, M. M., Badruzzaman, A. T. M., Sikder, M. H., Islam, M. R., Rahman, M. T., Alam, J., & Ashour, H. M. (2023) · Biomedicines · doi:10.3390/biomedicines11112937 · Cited by 337
Escherichia coli: an old friend with new tidings
Vila, J., Sáez-López, E., Johnson, J. R., Römling, U., Dobrindt, U., Cantón, R., Giske, C. G., Naas, T., Carattoli, A., Martínez-Medina, M., et al. (2016) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuw005 · Cited by 335
Tamma, P. D., Han, J. H., Rock, C., Harris, A. D., Lautenbach, E., Hsu, A. J., Avdic, E., & Cosgrove, S. E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ003 · Cited by 314
An update on the management of urinary tract infections in the era of antimicrobial resistance
Bader, M. S., Loeb, M., & Brooks, A. A. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1246055 · Cited by 261
β-Lactam/β-Lactamase Inhibitor Combinations: From Then to Now
Toussaint, K. A., & Gallagher, J. C. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014556652 · Cited by 136
Tansarli, G. S., Poulikakos, P., Kapaskelis, A., & Falagas, M. E. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt500 · Cited by 87
Self-citationAlevizakos, M., Karanika, S., Detsis, M., & Mylonakis, E. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.08.021 · Cited by 77
Metadata
- Authors
- Vardakas, K. Z., Tansarli, G. S., Rafailidis, P. I., & Falagas, M. E.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-21
- Volume
- 67
- Issue
- 12
- Pages
- 2793-2803
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2149315953
- Cited by
- 354
- References
- 34
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.